developing

Vertical AI acquires equity stake in Levangie Labs to supercharge platform capabilities

WILLEMSTAD, Curaçao, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vertical AI, is a leading AI no-code customization company behind Vertical Studio,…

1 day ago

Litmus7 Doubles Down on Generative AI with New Innovation Hub

Litmus7 Inc. has launched an AGI innovation hub as part of its new 'Advait' initiative, focused on developing a human-centered…

1 day ago

Anteris Announces Results for the Second Quarter of 2025

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR,…

3 days ago

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25,…

3 weeks ago

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

July 18, 2025 16:05 ET  | Source: HOOKIPA Pharma Inc. NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) --…

4 weeks ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

July 08, 2025 21:36 ET  | Source: Cogent Biosciences, Inc. WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE)…

1 month ago

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team Egham, UK – 03 July 2025…

1 month ago

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to…

2 months ago

Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions

Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. Preclinical…

2 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 19:30 ET  | Source: Structure Therapeutics Inc. SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics…

2 months ago